FRACTION-Lung : A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II trial is assessing four combination immunotherapies for the treatment of advanced Non-Small Cell (NSC) Lung Cancer.
 

This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer

Commercial Sponsor

Bristol-Myers Squibb (BMS)

Summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is more effective than Nivolumab by itself in patients with advanced Non-Small Cell lung cancer.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Ms Karen Gillett
Karen.Gillett@monashhealth.org
(03) 8572 2018

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next